Theranostics 2018; 8(16):4393-4408. doi:10.7150/thno.26869 This issue

Review

State-of-the-art of microbubble-assisted blood-brain barrier disruption

Kang-Ho Song1, Brandon K. Harvey2, Mark A. Borden1✉

1. Department of Mechanical Engineering, University of Colorado, Boulder, CO 80309
2. Intramural Research Program, National Institute on Drug Abuse, Baltimore, MD 21224

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Citation:
Song KH, Harvey BK, Borden MA. State-of-the-art of microbubble-assisted blood-brain barrier disruption. Theranostics 2018; 8(16):4393-4408. doi:10.7150/thno.26869. Available from https://www.thno.org/v08p4393.htm

File import instruction

Abstract

Graphic abstract

Focused ultrasound with microbubbles promises unprecedented advantages for blood-brain barrier disruption over existing intracranial drug delivery methods, as well as a significant number of tunable parameters that affect its safety and efficacy. This review provides an engineering perspective on the state-of-the-art of the technology, considering the mechanism of action, effects of microbubble properties, ultrasound parameters and physiological variables, as well as safety and potential therapeutic applications. Emphasis is placed on the use of unified parameters, such as microbubble volume dose (MVD) and ultrasound mechanical index, to optimize the procedure and establish safety limits. It is concluded that, while efficacy has been demonstrated in several animal models with a wide range of payloads, acceptable measures of safety should be adopted to accelerate collaboration and improve understanding and clinical relevance.

Keywords: focused ultrasound, ultrasound contrast agent, drug delivery, gene therapy